The University of Chicago Header Logo

Connection

Wendy Stock to Adolescent

Back to Details
This is a "connection" page, showing publications Wendy Stock has written about Adolescent.
Wendy Stock
Connection Strength
1.851
Adolescent
  1. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.096
  2. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4085-4092.
    View in: PubMed
    Score: 0.085
  3. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 06; 11(6):1440-1453.
    View in: PubMed
    Score: 0.077
  4. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512.
    View in: PubMed
    Score: 0.076
  5. Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57.
    View in: PubMed
    Score: 0.073
  6. Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. JCO Oncol Pract. 2020 05; 16(5):231-238.
    View in: PubMed
    Score: 0.071
  7. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559.
    View in: PubMed
    Score: 0.066
  8. Management of acute lymphoblastic leukemia in young adults. Clin Adv Hematol Oncol. 2018 Feb; 16(2):138-146.
    View in: PubMed
    Score: 0.062
  9. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
    View in: PubMed
    Score: 0.058
  10. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017 03; 101(3):391-395.
    View in: PubMed
    Score: 0.057
  11. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017 06; 17(3):274-279.
    View in: PubMed
    Score: 0.055
  12. How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood. 2015 Jun 11; 125(24):3702-10.
    View in: PubMed
    Score: 0.051
  13. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8.
    View in: PubMed
    Score: 0.042
  14. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec; 52(12):2237-53.
    View in: PubMed
    Score: 0.040
  15. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec; 45(12):1692-8.
    View in: PubMed
    Score: 0.036
  16. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010:21-9.
    View in: PubMed
    Score: 0.035
  17. Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep. 2008 Jul; 3(3):144-51.
    View in: PubMed
    Score: 0.032
  18. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 01; 112(5):1646-54.
    View in: PubMed
    Score: 0.032
  19. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
    View in: PubMed
    Score: 0.031
  20. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.026
  21. Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3478-3490.
    View in: PubMed
    Score: 0.024
  22. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Adv. 2024 06 25; 8(12):3226-3236.
    View in: PubMed
    Score: 0.024
  23. Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL. JCO Oncol Pract. 2024 Apr; 20(4):491-502.
    View in: PubMed
    Score: 0.023
  24. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
    View in: PubMed
    Score: 0.023
  25. Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017. Cancer. 2024 03 01; 130(5):750-769.
    View in: PubMed
    Score: 0.023
  26. A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023 09 26; 7(18):5202-5209.
    View in: PubMed
    Score: 0.023
  27. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022 06 16; 139(24):3519-3531.
    View in: PubMed
    Score: 0.021
  28. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 07; 35(7):2076-2085.
    View in: PubMed
    Score: 0.019
  29. Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun. 2021 02 26; 12(1):1334.
    View in: PubMed
    Score: 0.019
  30. Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1289-305, viii-ix.
    View in: PubMed
    Score: 0.019
  31. New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep. 2020 12; 15(6):424-435.
    View in: PubMed
    Score: 0.019
  32. Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. Biol Blood Marrow Transplant. 2020 12; 26(12):2335-2345.
    View in: PubMed
    Score: 0.019
  33. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020 06; 95(6):583-593.
    View in: PubMed
    Score: 0.018
  34. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood. 2000 Apr 01; 95(7):2364-71.
    View in: PubMed
    Score: 0.018
  35. Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2020 03; 21(3):421-435.
    View in: PubMed
    Score: 0.018
  36. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327.
    View in: PubMed
    Score: 0.017
  37. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487.
    View in: PubMed
    Score: 0.017
  38. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol. 2019 04; 94(4):408-416.
    View in: PubMed
    Score: 0.017
  39. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307.
    View in: PubMed
    Score: 0.017
  40. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer. 2019 03; 66(3):e27542.
    View in: PubMed
    Score: 0.016
  41. Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. JAMA Oncol. 2018 05 01; 4(5):725-734.
    View in: PubMed
    Score: 0.016
  42. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018 Jun; 24(4):299-308.
    View in: PubMed
    Score: 0.015
  43. Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma. Leukemia. 2017 06; 31(6):1450-1453.
    View in: PubMed
    Score: 0.015
  44. Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome. Cancer Epidemiol Biomarkers Prev. 2017 03; 26(3):312-320.
    View in: PubMed
    Score: 0.015
  45. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017 04; 58(4):950-958.
    View in: PubMed
    Score: 0.014
  46. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016 12; 48(12):1481-1489.
    View in: PubMed
    Score: 0.014
  47. Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. Cancer. 2017 Jan 01; 123(1):122-130.
    View in: PubMed
    Score: 0.014
  48. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 01; 31(1):34-39.
    View in: PubMed
    Score: 0.014
  49. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53.
    View in: PubMed
    Score: 0.014
  50. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072.
    View in: PubMed
    Score: 0.014
  51. Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. Cancer. 2016 Mar 15; 122(6):954-61.
    View in: PubMed
    Score: 0.013
  52. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015 Sep 25; 5:e350.
    View in: PubMed
    Score: 0.013
  53. Inclusion of Adolescents and Young Adults in Cancer Clinical Trials. Semin Oncol Nurs. 2015 Aug; 31(3):197-205.
    View in: PubMed
    Score: 0.013
  54. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. Oncotarget. 2014 Dec 15; 5(23):12371-82.
    View in: PubMed
    Score: 0.012
  55. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015 Jan 22; 125(4):680-6.
    View in: PubMed
    Score: 0.012
  56. Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. Leukemia. 1994 Nov; 8(11):1918-22.
    View in: PubMed
    Score: 0.012
  57. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11; 371(11):1005-15.
    View in: PubMed
    Score: 0.012
  58. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014 Jul; 55(7):1523-32.
    View in: PubMed
    Score: 0.012
  59. Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012 Sep 06; 120(10):2098-108.
    View in: PubMed
    Score: 0.011
  60. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15.
    View in: PubMed
    Score: 0.010
  61. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Oct; 59(4):662-7.
    View in: PubMed
    Score: 0.010
  62. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11; 116(19):3751-7.
    View in: PubMed
    Score: 0.009
  63. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21.
    View in: PubMed
    Score: 0.009
  64. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
    View in: PubMed
    Score: 0.009
  65. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1.
    View in: PubMed
    Score: 0.009
  66. Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. Biol Blood Marrow Transplant. 2008 Aug; 14(8):938-41.
    View in: PubMed
    Score: 0.008
  67. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10.
    View in: PubMed
    Score: 0.007
  68. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13.
    View in: PubMed
    Score: 0.006
  69. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant. 2003 May; 31(9):813-6.
    View in: PubMed
    Score: 0.006
  70. [Rational EDP-basic documentation in the surgical clinic]. Chirurg. 1982 Mar; 53(3):176-83.
    View in: PubMed
    Score: 0.005
  71. [Reimplantation of peripheral parts of the extremities. 808 cases and functional results]. Minerva Chir. 1981 Oct 31; 36(20):1337-44.
    View in: PubMed
    Score: 0.005
  72. [Characteristics of normal cross-sectional anatomy of the skin in high resolution magnetic resonance tomography]. Hautarzt. 1997 Jan; 48(1):26-30.
    View in: PubMed
    Score: 0.004
  73. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. Bone Marrow Transplant. 1995 Nov; 16(5):655-61.
    View in: PubMed
    Score: 0.003
  74. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. Leukemia. 1995 Mar; 9(3):433-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.